Design Therapeutics, Inc. (DSGN)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1807120 · fiscal year ends in Dec
Closing price $11.09 on 29 Oct 2026; 52-week range $6.24 to $15.94.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $0
- Net income, last twelve months
- -$70.8M
- Earnings per share
- -$1.18
- Free cash flow
- -$55.1M
- Return on equity
- -35.1%
- Market value
- $694.0M
- Cash
- $12.9M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 62.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $0 | -$79.5M | -$69.8M | -$1.22 | -$54.6M | 10-K filed 9 Mar 2026 |
| FY2024 | 31 Dec 2024 | $0 | -$62.4M | -$49.6M | -$0.88 | -$43.4M | 10-K filed 10 Mar 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$20.2M | -$0.32 |
| Q1 FY2026 | 31 Mar 2026 | $0 | -$17.6M | -$0.29 |
| Q4 FY2025 | 31 Dec 2025 | $0 | -$16.0M | -$0.27 |
| Q3 FY2025 | 30 Sep 2025 | $0 | -$17.0M | -$0.30 |
| Q2 FY2025 | 30 Jun 2025 | $0 | -$19.1M | -$0.34 |
| Q1 FY2025 | 31 Mar 2025 | $0 | -$17.7M | -$0.31 |
Company events
The newest 8-K filings of 38 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 3 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 11 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 18 May 2026 | 8-K | Other events | 8.01 |
| 28 Apr 2026 | 8-K | Results, Investor update | 2.02, 7.01 |
| 1 Apr 2026 | 8-K | Leadership change | 5.02 |
| 9 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Jan 2026 | 8-K | Leadership change | 5.02 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 10 Sep 2025 | 8-K | Leadership change | 5.02 |
| 7 Aug 2025 | 8-K | Results, Investor update | 2.02, 7.01 |
| 12 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 7 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 108 held.
| Filed | Form | Period |
|---|---|---|
| 3 Aug 2026 | 10-Q | 30 Jun 2026 |
| 3 Aug 2026 | 8-K | 3 Aug 2026 |
| 11 Jun 2026 | 8-K | 9 Jun 2026 |
| 18 May 2026 | 8-K | 18 May 2026 |
| 28 Apr 2026 | 10-Q | 31 Mar 2026 |
| 28 Apr 2026 | 8-K | 28 Apr 2026 |
| 23 Apr 2026 | DEFA14A | – |
| 23 Apr 2026 | DEF 14A | 23 Apr 2026 |
| 23 Apr 2026 | ARS | 31 Dec 2025 |
| 1 Apr 2026 | 8-K | 31 Mar 2026 |
| 9 Mar 2026 | S-8 | – |
| 9 Mar 2026 | 10-K | 31 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 18 Nov 2025 | Logos Global Master Fund LP, Director | 120,000 | $891.6K | 18 Nov 2025 |
| 14 Nov 2025 | Logos Global Master Fund LP, Director | 620,000 | $4.4M | 14 Nov 2025 |
| 7 Nov 2025 | Logos Global Master Fund LP, Director | 415,000 | $2.9M | 7 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Point72 Asset Management, L.P. | 13G amended | 3.8% | 2.4M |
| 14 Aug 2026 | Sirenia Capital Management LP | 13G | 9.5% | 6.0M |
| 9 Jun 2026 | Point72 Asset Management, L.P. | 13G | 5.1% | 3.2M |
| 15 May 2026 | Point72 Asset Management, L.P. | 13G amended | 4.4% | 2.7M |
| 11 Mar 2026 | SR One Capital Fund I Aggregator, LP | 13D amended | 10.7% | 6.6M |
| 17 Feb 2026 | Point72 Asset Management, L.P. | 13G amended | 9.4% | 5.4M |
| 18 Nov 2025 | Logos Global Management LP | 13D amended | 4.4% | 2.5M |
| 12 Nov 2025 | Logos Global Management LP | 13D amended | 5.7% | 3.3M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 6.7M | +0.56% | 11.99 |
| 30 Sep 2026 | 6.6M | +21.15% | 8.69 |
| 15 Sep 2026 | 5.5M | -1.46% | 7.26 |
| 31 Aug 2026 | 5.5M | -6.47% | 8.98 |
| 14 Aug 2026 | 5.9M | -0.45% | 15.23 |
| 31 Jul 2026 | 6.0M | +4.99% | 11.96 |
| 15 Jul 2026 | 5.7M | -0.81% | 6.36 |
| 30 Jun 2026 | 5.7M | +23.4% | 5.16 |
Funds that hold it
From each fund's latest Form 13F.
152 funds held it at 30 Jun 2026: 87 added and 32 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| SR One Capital Management, LP | 6,526,476 | $94.4M | 0 |
| Logos Global Management LP | 3,000,000 | $43.4M | +1,050,000 |
| Baker Bros. Advisors LP | 2,678,430 | $38.8M | +92,452 |
| Driehaus Capital Management LLC | 2,661,115 | $38.5M | +916,128 |
| BlackRock, Inc. | 2,660,024 | $38.5M | +526,260 |
| Point72 Asset Management, L.P. | 2,366,453 | $34.2M | -356,301 |
| Trails Edge Capital Partners, LP | 2,001,282 | $29.0M | +1,149,269 |
| Frazier Life Sciences Management, L.P. | 1,809,854 | $26.2M | +1,809,854 |
| Vivo Capital, LLC | 1,612,903 | $23.3M | 0 |
| Vanguard Capital Management LLC | 1,571,022 | $22.7M | +221,172 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B